New blood test to predict antibody-mediated rejection to be presented at World Transplant Congress

21, Apr 2025


New blood test to predict antibody-mediated rejection to be presented at World Transplant Congress

News osutra_adm1n

SAN FRANCISCO — August, 2025. Antibody-mediated rejection causes severe graft injury and graft loss. New biomarkers are needed to manage this type of rejection. In a clinical trial conducted at three kidney transplant centers, the
PlexABMRTM test developed by Plexision predicted antibody-mediated rejection with positive and negative predictive values of 81% and 75%, respectively. Study results will be presented in San Francisco in early August, 2025 at the World Transplant Congress.

Categories

Recent Posts

  • …
  • …
  • T-cell and antibody immunity after COVID-19 vaccination
    …

logo

Developing cellular biomarkers for personalized diagnosis and drug development in infectious diseases, solid organ transplantation, as well as immunological disorders.

CONTACT US

  • Contact us
    4424 Penn Ave., #202,
    Pittsburgh, PA 15224 USA
  • Mail Us
    info@plexision.com
  • Phone
    +1 (855) 753-9474
© Copyright Plexision 2020. All Rights Reserved.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact